Business
Cardax Refutes Allegations by Competitive Trade Group, NAXA
Cardax Refutes Allegations by Competitive Trade Group, NAXA.
About this update from Cardax Inc
[{"type":"text","content":"\n\n\n\nCardax Refutes Allegations by Competitive Trade Group, NAXA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntbls{\nBORDER-TOP: black 1px solid; BORDER-RIGHT: black 1px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid\n}\n\n\n\n\n\n\nCardax Refutes Allegations by Competitive Trade Group, NAXA\nCardax also Demands that NAXA Immediately Stop Making \"Reckless and Unsupported\" Statements that Misinform Consumers and Create Market Confusion\nPR Newswire\nHONOLULU, Dec. 5, 2017\n\n\n\nHONOLULU, Dec. 5, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today refuted numerous false and baseless allegations made by the Natural Algae Astaxanthin Association (\"NAXA\") in a \"citizen\" petition that it recently filed with the Food and Drug Administration (\"FDA\"). NAXA is a small trade group with four members: Cyanotech Corporation (manufacturer of BioAstin®), Algatechnologies, Algae Health Sciences, Inc., and Alphy Biotech – each of which markets astaxanthin products made from poorly characterized microalgal extracts in direct competition with Cardax's premium astaxanthin dietary supplement, ZanthoSyn®.\n\nZanthoSyn®, Cardax's premium astaxanthin dietary supplement for inflammatory health and longevity, is supported by more than 1,500 peer reviewed papers and 50 proof-of-concept human clinical studies, and the product carries a GRAS (\"Generally Recognized as Safe\") safety designation in accordance with FDA regulations. Moreover, ZanthoSyn® offers superior purity and absorption advantages compared to microalgal astaxanthin.*\n\n\"We are fully confident in the anti-inflammatory health benefits, safety, and regulatory status of ZanthoSyn®. NAXA's allegations are simply spurious and do not present a good faith, scientifically credible a...